TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03079999

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: Twice daily aspirin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Twice daily placebo
Study: NCT04606290

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: O2matic HOT
Description: Automated oxygen titration with O2matic HOT

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Oxygen concentrator
Description: Fixed dose oxygen flow from concentrator
Study: NCT03880422

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Intervention
Description: Complete exercise program

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey Administration
Description: Ancillary studies
Study: NCT02036931

Intervention type: DEVICE
Intervention: Metal on Polyethylene articulation
Description: G7 Acetabular Cup System with Metal head on Polyethylene liner articulation (MOP)

Intervention type: DRUG
Intervention: Ceramic on Polyethylene articulation
Description: G7 Acetabular Cup System with Ceramic head on Polyethylene liner articulation (COP)

Intervention type: DEVICE
Intervention: Ceramic on Ceramic articulation
Description: G7 Acetabular Cup System with Ceramic head on Ceramic linear articulation (COC) - Outside the United States ONLY
Study: NCT04204408

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC0365-3769 (Mim8)
Description: Mim8 administered subcutaneously (s.c., under the skin). The treatment period will consist of 12 once-weekly doses or 3 once-monthly doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC0365-3769 (Mim8)
Description: Mim8 administered subcutaneously (s.c., under the skin). The treatment period will consist of 12 once-weekly doses or 3 once-monthly doses

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (Mim8)
Description: Mim8 placebo administered subcutaneously (s.c., under the skin)
Study: NCT04166487

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: predetermined dose, once per cycle via IV will be administered every 3 weeks, with 21 consecutive days defined as a treatment cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: predetermined dose, once per cycle via IV will be administered every 3 weeks, with 21 consecutive days defined as a treatment cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: predetermined dose, once per cycle via IV will be administered every 3 weeks, with 21 consecutive days defined as a treatment cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEMETREXED
Description: administered per standard practice, once per cycle via IV will be administered every 3 weeks, with 21 consecutive days defined as a treatment cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CARBOPLATIN
Description: administered per standard practice once per cycle via IV will be administered every 3 weeks, with 21 consecutive days defined as a treatment cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PACLITAXEL
Description: administered per standard practice once per cycle via IV will be administered every 3 weeks, with 21 consecutive days defined as a treatment cycle.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: InVision
Description: Plasma draw for clinical test performed at C1D1 and C2D1; plasma draw for research testing performed at other timepoints per protocol.
Study: NCT03732820

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: olaparib
Description: 300 mg (2 x 150 milligrams (mg) tablets) twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: abiraterone acetate
Description: 1000 milligrams (mg) once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: abiraterone acetate
Description: 1000 milligrams (mg) once daily
Study: NCT03960710

Intervention type: OTHER
Intervention: Anonymized CT examinations
Description: The anonymized CT examinations will be reviewed in Lyon, in the imaging department of Edouard Herriot Hospital, by an expert radiologist and an intern from the Lyon hospitals.

Intervention type: OTHER
Intervention: Anonymized CT examinations
Description: The anonymized CT examinations will be reviewed in Lyon, in the imaging department of Edouard Herriot Hospital, by an expert radiologist and an intern from the Lyon hospitals.

Intervention type: OTHER
Intervention: Training (1)
Description: An initial training phase of the artificial intelligence network will be carried out :~- Segmentation of the livers of a first part of the CT examination, by an intern of the Lyon hospitals

Intervention type: OTHER
Intervention: Training (2)
Description: An initial training phase of the artificial intelligence network will be carried out :~- Use of computer data to drive the artificial intelligence network.

Intervention type: OTHER
Intervention: Validation (1)
Description: A validation phase of the artificial intelligence tool will be carried out with segmentation of the livers of the second part of the CT examinations :~- Carried out by an intern at the Lyon hospitals
Study: NCT06637683

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: LiveSpo COLON
Description: LiveSpo® COLON has a registration number: 10401/2019/ĐKSP issued by the Food Safety Department of the Ministry of Health in Vietnam
Study: NCT03960710

Intervention type: OTHER
Intervention: Validation (2)
Description: A validation phase of the artificial intelligence tool will be carried out with segmentation of the livers of the second part of the CT examinations :~- Carried out by the neural network
Study: NCT06637683

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Routine treatment
Description: The standard internal medicine treatment protocol of the hospital
Study: NCT03890094

Intervention type: DRUG
Intervention: Sufentanil
Description: Patients were applied sufentanil and midazolam intravenously and topical anesthetized.
Study: NCT03112928

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Phantom Motor Execution
Description: Neuromotus - PME decodes motor volition applying machine learning to surface electromyography. Once the intention of movement is known, this is use to control serious games in virtual and augmented reality.~A treatment session of MPE consists of:~1. Pain evaluation~2. Placement of the electrodes and fiducial marker~3. Practice of motor execution in Augmented Reality (AR)~4. Gaming using phantom movements~5. Practice of motor execution by matching random target postures of a virtual limb.~Step 3 to 4 are repeated for different phantom joints, initially one at the time progressing to several joints simultaneously. A treatment session last 2 hours.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Phantom Motor Imagery
Description: The only difference between PME and PMI is that in the former myoelectric signals are used to give the participants control over the virtual environments, whereas in PMI the presence of myoelectric activity is used as an alarm to remind the participant that it must imagine rather than execute the phantom movement. In PMI the virtual environments act autonomously to guide the participant in imagination of movement.
Study: NCT03734107

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Plan, Reflect, and Engage with Providers for Diabetes Care
Description: Behavioral intervention designed to improve health communication skills and readiness for adult diabetes care
Study: NCT00543829

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin, docetaxel, tamoxifen
Description: Every 14 days to a total of 4 cycles of doxorubicin (50 mg/m², 15 minutes i.v. infusion) and docetaxel (75 mg/m², 1 hour i.v. infusion) with tamoxifen (30 mg tablet p.o. for 5 years post surgery)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: doxorubicin, docetaxel
Description: Every 14 days to a total of 4 cycles of doxorubicin (50 mg/m², 15 minutes i.v. infusion) and docetaxel (75 mg/m², 1 hour i.v. infusion)
Study: NCT03018782

Intervention type: OTHER
Group type: OTHER
Intervention: Brief Pain Inventory Short Form
Description: Brief Pain Inventory Short Form
Study: NCT03088293

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Infliximab
Description: Patients will receive prednisone and infliximab (5 mg/kg at week 0, 2, 6, 11 and 16 as an intravenous (IV) infusion) in association with low-dose methotrexate (10 mg/week) for 16 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Patients will receive prednisone and cyclophosphamide intravenously (700 mg/m2 every 4 weeks intravenously) (n=25) for 16 weeks.
Study: NCT04438746

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Emotion discussion
Description: General discussion of emotions; no therapy or training is offered

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Affective Therapy
Description: Active training in regulating anger
Study: NCT02028364

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: 10mg orally daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exemestane
Description: 25mg orally daily
Study: NCT03661073

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Assessment of motor imagery ability
Description: The intervention will last 3 hours ± 45 minutes, the assessment will be spread over 3 sessions of 1 hour ± 15 minutes on one week. The time between two sessions will depend on patient fatigability and availability. The VMIQ-2 and the KVIQ-20 will be realized during the first session. In the second session, patients will perform the hand laterality judgment task and the MIQ-RS. During the last session the Timed up and go and the box and block test will be realized.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Assessment of motor imagery ability of healthy subject
Description: The intervention will last 2 hours ± 15 minutes. All the tests will be spread over 1 session. Assessment order will be VMIQ-2, KVIQ-20, the hand laterality judgment task, the after a break MIQ-RS, iTUG and iBBT.
Study: NCT03124615

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzalutamide
Description: Enzalutamide is a FDA and Therapeutic Goods Administration (TGA, Regulatory Authority of therapeutic goods in Australia) approved treatment for castration resistant prostate cancer
Study: NCT00610220

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Fiberglass short arm cast
Description: Cast will be applied for a 4-week period

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Prefabricated wrist splint
Description: Splint will be applied for a 4-week period
Study: NCT04833738

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hyaluronic acid

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Corticosteroids Triamcinolone Acetonide
Description: triamcinolone acetonide, 40 mg/ml, single dose

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Electrotherapy
Description: electrotherapy
Study: NCT01374854

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Umbilical mesenchymal stem cell (UC-MSCs) infusion
Description: 1×10\^6/kg UC-MSCs is infused through pancreatic artery along with mononuclear cells by interventional therapy and another same dose of UC-MSCs is administered one week post-intervention.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: traditional therapy
Description: exogenous insulin injection daily
Study: NCT01739777

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ucMSC
Description: 1 million mesenchymal cells per Kg weight injected intravenously in allogenic AB plasma

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Controls
Description: Autologous Serum will administrated as placebo
Study: NCT03868228

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pressurised Intraperitoneal Aerosol Chemotherapy (PIPAC)
Description: Use of CapnoPen device to aerosolise Oxaliplatin 92mg/m2 chemotherapy 6-8 weekly intervals for intraperitoneal distribution via laparoscopy.
Study: NCT03242278

Intervention type: DRUG
Intervention: Rivaroxaban (Xarelto, BAY59-7939)
Description: As prescribed by treating physicians

Intervention type: DRUG
Intervention: Rivaroxaban (Xarelto, BAY59-7939)
Description: As prescribed by treating physicians
Study: NCT05431413

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Control group: Fluoxetine and Placebo
Description: Cap Fluoxetin 20mg OD for four weeks and injection 100ml normal saline(NS) BD for two weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Experimental group: Fluoxetine and ATP
Description: Cap Fluoxetin 20mg OD for four weeks and injection ATP 100mg in NS BD for two weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Control group: Fluoxetine and Phosphocreatine
Description: Cap Fluoxetin 20mg OD for four weeks and injection Phosphocreatine 1g in NS BD for two weeks.
Study: NCT03332108

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EpxBreastfeeding
Description: We developed an algorithm using the Epharmix platform, an automated toll-free phone and text message-based system that can programmatically query patients via their personal phones and subsequently collect response data, allowing clinically-relevant responses to trigger alerts to designated healthcare providers. The intervention for breastfeeding, hereafter referred to as EpxBreastfeeding, was built using significant clinical and patient input to only ask the most clinically-relevant questions for breastfeeding in a multiple-choice manner, such as In the past \[x\] days, have you fed your baby 1) breast milk only, 2) breast milk and formula or 3) formula only?. These communications elicit patient-reports of breastfeeding at intervals of interest for the provider, which is, on average, every 2 days in the first three weeks postpartum and every 5 days subsequently. All data is filtered by clinician-designed algorithms to stratify patients into categories.
Study: NCT04318938

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brigatinib
Description: Treatment with Brigatinib

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tyrosine kinase inhibitor
Description: Treatment with any TKI
Study: NCT03332108

Intervention type: OTHER
Group type: OTHER
Intervention: Baby book survey
Description: We developed a baby book template that will be given to mothers allowing them to make note of dates related to their child's development during the first year. Examples include: When was baby's first appointment with his/her pediatrician? When did you add formula into baby's feeding? When did you start feeding baby only formula? When did you introduce solid food into baby's diet? When did baby first smile? When did you start reading to baby? What was the first book you read to baby? Whe

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Baby book survey
Description: We developed a baby book template that will be given to mothers allowing them to make note of dates related to their child's development during the first year. Examples include: When was baby's first appointment with his/her pediatrician? When did you add formula into baby's feeding? When did you start feeding baby only formula? When did you introduce solid food into baby's diet? When did baby first smile? When did you start reading to baby? What was the first book you read to baby? Whe
Study: NCT03771144

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: arthrolysis
Description: Surgery is performed under general anesthesia. The usual duration of this surgery is on average 1h30. This surgery requires an anterior approach and a posterior approach. The patient is placed in lateral decubitus. The arthroscope of 2.7 is introduced by a posterior route. An anterior instrumental track is made from inside out through the rotator interval.
Study: NCT03681652

Intervention type: DRUG
Intervention: Azathioprine
Description: Children with Crohn's disease who are treated with azathioprine for post-operative prophylaxis following ileo-cecal resection

Intervention type: DRUG
Intervention: Anti-TNF Drug
Description: Children with Crohn's disease who are treated with anti-TNF monotherapy for post-operative prophylaxis following ileo-cecal resection
Study: NCT00527111

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-fluorouracil

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil
Study: NCT02516813

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M3814 100 mg
Description: Participants received 100 mg of M3814 as capsule or tablet orally once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M3814 100 mg
Description: Participants received 100 mg of M3814 as capsule or tablet orally once daily.
Study: NCT00527111

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Pelvic irradiation

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Pelvic irradiation
Study: NCT02516813

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M3814 100 mg
Description: Participants received 100 mg of M3814 as capsule or tablet orally once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M3814 200 mg
Description: Participants received 200 mg of M3814 as capsule or tablet orally once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M3814 200 mg
Description: Participants received 200 mg of M3814 as capsule or tablet orally once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M3814 200 mg
Description: Participants received 200 mg of M3814 as capsule or tablet orally once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M3814 300 mg
Description: Participants received 300 mg of M3814 as capsule or tablet orally once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M3814 300 mg
Description: Participants received 300 mg of M3814 as capsule or tablet orally once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M3814 400 mg
Description: Participants received 400 mg of M3814 as capsule or tablet orally once daily.
Study: NCT02996539

Intervention type: OTHER
Intervention: Clinical examination and laboratory measurements
Description: Subjects were interviewed by a physician regarding their medical history, history of hypoglycemic attacks, smoking status, and alcohol consumption. Concentrations of blood urea nitrogen (BUN) and serum creatinine (SCr) were analyzed by the urease-ultraviolet rate method and picric acid method, respectively. Serum uric acid was determined using the enzymatic colorimetric method. Serum hemoglobin A1c (HbA1c) was measured by liquid enzymatic assay. Urine albumin and urine creatinine were found through immune turbidimetric analysis and the enzymatic method, respectively.
Study: NCT02244398

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: FP and HTC services
Description: In this project, VHTs already providing family planning services are trained to offer HIV testing and counseling services (HTC).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: FP services
Description: VHTs in the control arm only provide family planning services
Study: NCT01838226

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Problem Solving
Description: A group problem-solving intervention, with interval phone calls delivered to check in on goal progress and reinforce group learning. Groups will meet monthly for 6 months, and each patient will be called once between each group session. Each group will consist of 10 patients. Problem-solving teaches patients to overcome internal barriers to healthful behaviors. Problem solving will be combined, at all group sessions, with self-efficacy training, so that patients will be taught simultaneously to overcome both internal and external barriers. Participants will be asked to develop personal goals related to CVD-related behaviors (e.g., smoking and weight reduction).
Study: NCT04391569

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ganaxolone
Description: Ganaxolone will be administered.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered.
Study: NCT03812848

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Anticoagulation Stewardship Program
Description: A clinical-pharmacist led anticoagulation stewardship program that includes:~1. Warfarin monitoring and dosing protocol. 1a.Warfarin initial dosing algorithm. 1b.Recommended International normalized ration (INR) target and duration of Warfarin therapy by indication.~1c.Warfarin dosage adjustment algorithms.~1d.Management of high INR values. 2-Heparin weight-based protocol. 3-Perioperative anticoagulation use protocol. 4-Policies that address baseline and ongoing laboratory monitoring for anticoagulants.~5-Protocol for Heparin Induced Thrombocytopenia(HIT) management. 6-Anticoagulation reversal protocol. 7-Booklet for anticoagulant drugs and all of previously prepared protocols. 8-Education programs regarding anticoagulation's therapy for health care team dealing with anticoagulation and patients.
Study: NCT02835105

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Surotomycin
Description: A single oral dose of either 0.5, 1, 2 or 4 g surotomycin in hard gelatin capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Surotomycin
Description: A single oral dose of either 0.5, 1, 2 or 4 g surotomycin in hard gelatin capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Surotomycin
Description: A single oral dose of either 0.5, 1, 2 or 4 g surotomycin in hard gelatin capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Surotomycin
Description: A single oral dose of either 0.5, 1, 2 or 4 g surotomycin in hard gelatin capsules

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A single oral dose of placebo for surotomycin in hard gelatin capsules
Study: NCT03470051

Intervention type: DIAGNOSTIC_TEST
Intervention: QT Ultrasound
Description: All subjects will be asked to agree to an ultrasound-guided breast needle biopsy by a qualified radiologist experienced in this procedure if not already completed prior to study entry.

Intervention type: DIAGNOSTIC_TEST
Intervention: QT Ultrasound
Description: All subjects will be asked to agree to an ultrasound-guided breast needle biopsy by a qualified radiologist experienced in this procedure if not already completed prior to study entry.